Severe acute respiratory syndrome-related coronavirus

Recce Pharmaceuticals Adds Biotech Veteran Alan W. Dunton M.D. to its Board of Directors

Retrieved on: 
Tuesday, July 14, 2020
Recce, Antibiotic, South African Special Forces, Severe acute respiratory syndrome-related coronavirus, Pharmaceutical industry, Military units and formations, Articles, Military, Draft:Recce Pharmaceuticals Ltd

On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.

Key Points: 
  • On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.
  • Alan joins us at a critical time as we move into the second half of 2020, where we anticipate a number of human clinical trials evaluating our broad-spectrum novel antibiotic, RECCE 327.
  • In addition, we will continue to investigate the efficacy of our synthetic compounds against SARS-CoV-2 among other key clinical development milestones.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Retrieved on: 
Monday, July 13, 2020
Health, Articles, Life sciences, Severe acute respiratory syndrome-related coronavirus, Fast track, Pfizer, Food and Drug Administration, Vaccines

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that two of the companies four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that two of the companies four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA).
  • The FDAs decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2, said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer.
  • We are pleased to have received Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical development path forward, said zlem Treci, Chief Medical Officer at BioNTech.
  • The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world.

Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.

Retrieved on: 
Monday, July 13, 2020
Medicine, Oxygen compounds, Organic compounds, Organic peroxides, Artemisinin, Commercialization of traditional medicines, Traditional Chinese medicine, Herbal medicine, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Key Points: 
  • Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
  • By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.
  • Like other potential COVID-19 therapeutic agents, the efficacy of Artemisinin remains to be tested in well-controlled and sufficiently powered clinical trials.
  • The reported results indicated that Artemisinin had an EC50 = 0.45 ug/ml and Safety Index = 140.

NovaBay Pharmaceuticals Announces Laboratory Results Confirm Avenova Kills SARS-CoV-2 (COVID-19 Virus)

Retrieved on: 
Monday, July 13, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Viruses, Chemical substances, Animal virology, Microbiology, Zoonoses, Coronaviridae, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, CoV, Disinfectant, Hypochlorous acid

(NYSE American: NBY) announces testing results from an independent third-party laboratory confirming that Avenova, NovaBays proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

Key Points: 
  • (NYSE American: NBY) announces testing results from an independent third-party laboratory confirming that Avenova, NovaBays proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.
  • Test results will be submitted to the Environmental Protection Agency (EPA) for the EPAs approved list of disinfectants for use against SARS-CoV-2.
  • Now we have results from a highly reputable independent laboratory confirming Avenova kills the coronavirus that causes COVID-19, said Justin Hall, NovaBay CEO.
  • The study was designed to determine Avenovas effectiveness against the SARS-CoV-2 on a hard surface.

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Retrieved on: 
Monday, July 13, 2020
Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Health, Articles, Life sciences, Severe acute respiratory syndrome-related coronavirus, Fast track, Pfizer, Food and Drug Administration, Vaccines, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that two of the companies four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that two of the companies four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA).
  • The FDAs decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2, said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer.
  • We are pleased to have received Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical development path forward, said zlem Treci, Chief Medical Officer at BioNTech.
  • The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world.

Vela Diagnostics receives CE-IVD approval and Provisional Authorisation from the Health Sciences Authority in Singapore for automated COVID-19 detection test

Retrieved on: 
Monday, July 13, 2020
Natural sciences, Branches of biology, Laboratory techniques, Molecular biology, Physical sciences, Severe acute respiratory syndrome-related coronavirus, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome, Polymerase chain reaction

SINGAPORE, July 13, 2020 /PRNewswire/ -- Vela Diagnostics announced today that an automated version of its COVID-19 detection test, the ViroKeySARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authority in Singapore.

Key Points: 
  • SINGAPORE, July 13, 2020 /PRNewswire/ -- Vela Diagnostics announced today that an automated version of its COVID-19 detection test, the ViroKeySARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authority in Singapore.
  • The ViroKey SARS-CoV-2 RT-PCR Test v2.0 is a probe-based reverse transcription PCR Test that detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome, specifically the ORF1a and N genes.
  • The automated test is optimized for a workflow consisting of theSentosa SX101 instrument, in conjunction with theSentosaSA201 instrument or the ABI 7500 Fast Dx.The automated workflow enables high throughput testing with significantly reduced hands-on time.
  • In April this year, an earlier version of the test, the ViroKey SARS-CoV-2 RT-PCR Test, also received the CE mark and Provisional Authorisation from the Health Sciences Authority in Singapore.

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

Retrieved on: 
Monday, July 13, 2020
Health, Medicine, Monoclonal antibodies, Severe acute respiratory syndrome-related coronavirus, Clinical trial, Neutralizing antibody

JS016 is the first COVID-19 neutralizing antibody entering clinical trials in China.

Key Points: 
  • JS016 is the first COVID-19 neutralizing antibody entering clinical trials in China.
  • JS016 is the first neutralizing antibody entering clinical trial in healthy subjects in the world.
  • Junshi Biosciences plans to initiate Phase Ib trial in non-severe COVID-19 patients and Phase II/III trials in severe and critical patients soon.
  • JS016 is in Phase I trial in China, which is the first clinical trial of a SARS-CoV-2 neutralizing antibody in healthy subjects in the world.

New England Biolabs' SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit Enables Visual Detection of Novel Coronavirus In 30 Minutes

Retrieved on: 
Friday, July 10, 2020
Viruses, Nidovirales, Zoonoses, Coronaviridae, Laboratory techniques, Health in Saudi Arabia, In Saudi Arabia, Middle East respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, CoV

IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.

Key Points: 
  • IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.
  • The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
  • "With the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, all you need is a simple heat source and 30 minutes to visually detect amplification of SARS CoV-2 RNA.
  • NEB,NEW ENGLAND BIOLABS, and WarmStart are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-sars-cov-2-r...

Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

Retrieved on: 
Friday, July 10, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Health, Medicine, Zoonoses, Clinical research, Severe acute respiratory syndrome-related coronavirus, CoV, Mucositis, Severe acute respiratory syndrome, Antibiotic, Clinical trial, Vaccine

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.
  • The Company expects to continue to comply with any applicable regulatory requirements with respect to discontinuing the clinical trial.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. relating to the development of novel antibiotics.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein, except as required by law.

Shareholder Alert: Robbins LLP Announces It Is Investigating Sorrento Therapeutics, Inc. (SRNE) for Misleading Shareholders

Retrieved on: 
Thursday, July 9, 2020
Legal, Professional services, Sorrento, Fiduciary, Severe acute respiratory syndrome-related coronavirus

Shareholder rights law firm Robbins LLP announces that it is investigating Sorrento Therapeutics, Inc. (NASDAQ: SRNE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that it is investigating Sorrento Therapeutics, Inc. (NASDAQ: SRNE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders.
  • Sorrento is a clinical stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.
  • If you suffered a loss as a result of Sorrento's misconduct, click here .
  • On May 15, 2020, Sorrento announced that it had discovered an antibody that had "demonstrated 100% inhibition of SARS-CoV-2 virus infection" and stated on national television "[Sorrento] want[s] to emphasize there is a cure."